AIS HealthCare™ is pleased to welcome Anish S. Patel, MD, MBA as Chief Medical Officer (CMO) where he will continue to advance our clinical and quality agenda to improve patient outcomes and therapy development.

As Chief Medical Officer, Dr. Patel will oversee and take an active role in the overall Quality of Pharmacy operations as well as enhancing the continuum of patient care through our Advanced Care Coordination Solutions (ACCS) and Advanced Nursing Solutions (ANS) offerings. In addition, Dr. Patel will help coordinate and expand our research and studies program, data analytics, therapy education and serve as a liaison between our Hospital Accounts, Neuromodulation and Pain Societies and Government Relations. In addition, he will lead the AIS Medical Advisory Board.

Dr. Patel is double-board certified in anesthesiology and pain medicine and currently serves as Vice-President and Managing Partner at National Spine and Pain Centers. He attended MGR Medical University, an affiliate of Harvard Medical International in India. Following medical school, he returned to Detroit where he completed a residency in Anesthesiology serving as chief resident in his final year before pursuing fellowship training in Interventional Pain Management at Brigham and Women’s Hospital, Harvard Medical School.

Dr. Patel is known for a truly multidisciplinary approach to pain management, utilizing interventional, medical and rehabilitative techniques. He strives to provide his patients with compassionate care to improve their lifestyle and sense of well-being.

Among his achievements, he has served as a member of the following professional organizations:

  • American Society of Interventional Pain Physicians
  • American Academy of Pain Medicine
  • North American Neuromodulation Society
  • American Society of Anesthesiologists
  • American Society of Anesthesiologists- Political Action Committee
  • American Society of Regional Anesthesia
  • American Medical Association
  • National Society for Healthcare Business Consultants

“I am very excited to join AIS HealthCare™ to continue to raise the bar on their already best-in-class quality and process standards to ultimately deliver infusion solutions for improved health outcomes and a better level of care,” stated Dr. Anish Patel, new Chief Medical Officer of AIS HealthCare™. “I look forward to continuing the Patient Safety. First!™ philosophy they have instilled in their employees.”

To learn more about AIS HealthCare™ and how the company is delivering on its unwavering commitment to patient safety, please visit

Dr. Patel may be reached at:

As the designated 503A provider with Premier, AIS Healthcare will offer its TDD pump medications to Premier’s alliance of 4,000 U.S. hospitals and 165,000 other providers.

The recently released 20% subcutaneous immunoglobulin therapy expands treatment options offered by Advanced Infusion Care.

Valdosta, GA—Advanced Infusion Care, a division of AIS Healthcare, now offers Xembify®, developed by Grifols for the treatment of primary immune deficiency disease (PIDD).

AIC’s nationally accredited home infusion teams collaborate closely with physicians to provide specialized in-home infusion services. This new therapy option, offered under a limited distribution partnership with Grifols, expands AIC’s ability to serve
immunoglobulin (Ig) infusion patients.

“We’re proud to be able to add Xembify® to our growing list of Ig infusion therapies,” said Jud Hall, Senior Vice President at AIS Healthcare. “This new therapy from Grifols can help us provide additional treatment options for our PIDD patients.”

Xembify® is for the treatment of PIDD in patients 2 years of age and older. Approved by the U.S. Food and Drug Administration on July 3, 2019, the therapy was launched in the United States on November 18 and is now available at all AIC locations.

Like all AIC patients, PIDD patients receive a high level of care from AIC, including 24/7 access to clinical and support staff. Every patient is assigned a dedicated team of professionals, including clinical pharmacists, infusion nurse specialists, patient care
managers and intake managers, to provide support throughout the treatment process.

For physicians, AIC is a full-service care delivery partner. We have contracts with multiple immunoglobulin suppliers like Grifols to help ensure prescribed therapies are always in stock. We also work directly with patients, insurance companies and physician offices to secure all needed authorizations and complete paperwork.

AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).

Physicians interested in AIC care services should contact their AIC representatives to get started or visit us at

About AIS Healthcare

Advancing quality. Improving lives.

As the nation’s top intrathecal and infusion care solutions provider, AIS Healthcare is committed to doing more of what matters for patients and providers. From the industry leading quality and sterility standards at our pharmacies to our comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do. Because when we do more to advance care quality, providers are empowered and patients are supported. Days get easier. Lives get better.

Learn more at

About Grifols

Grifols is a global healthcare company with more than 75 years of history improving the health and well-being of people around the world. Grifols produces essential plasma medicines for patients and provides hospitals, pharmacies and healthcare professionals with the tools, information and services they need to efficiently deliver expert medical care. Grifols’ three divisions—Bioscience, Diagnostic and Hospital—develop, produce and market innovative products and services available in more than 100 countries.

Learn more at

AIS Healthcare is proud to announce that its two state-of-the-art 503A compounding pharmacies and its four Advanced Infusion Care locations have received the prestigious URAC accreditation in Specialty Pharmacy, and its Dallas-based Care Coordination Program has been awarded URAC accreditation for Health Call Center.

AIS Healthcare opened its second 503A specialty compounding pharmacy in Dallas, creating a fully redundant targeted drug delivery operation that goes beyond state and industry standards to produce medications of the highest quality.

The acquisition marks AIS Healthcare’s expansion into ophthalmology and a continuation of its commitment to providing patient-specific medication of the highest quality.

Simon Castellanos

March 16, 2020

COVID-19 response: AIS Healthcare continues to go above and beyond to protect patients and support providers

In addition to our industry-leading safety and quality standards across all three of our care divisions, AIS Healthcare is implementing additional measures in response to COVID-19.

Dallas, Texas—AIS Healthcare is committed to doing what’s right, not just what’s expected, in response to the coronavirus disease 2019 (COVID-19).

From pharmacies that put patient safety first to highly skilled nurses dedicated to doing more for patients and providers, AIS Healthcare has the standards, procedures and services in place to support patients and
providers during this time:

  • We exceed industry safety and sterility standards in our pharmacies, including more robust environmental monitoring, and have an independent, full-time quality team on site
  • Our comprehensive care services give patients flexibility in where they receive care
  • We offer 24/7 nursing and pharmacist support for patients and providers

We will continue to go above and beyond across our three divisions.

Targeted Drug Delivery:

  • With a proven, proprietary process that combines aseptic processing with terminal sterilization—a pharmaceutical industry standard—we are able to achieve sterility assurance of 1:1,000,000 and a Beyond-Use Date of 21 to 45 days for all formulary medications1
  • Our state-of-the-art 503A compounding pharmacies in Dallas, Texas, and Ridgeland, Mississippi, are fully redundant, allowing for uninterrupted supply of medication to our patients
  • By exceeding USP <797> standards for particle testing, we are able to quickly detect contaminants, and use virucidal disinfectants in our cleanings
  • None of our active pharmaceutical ingredients are sourced from outside countries affected by the virus, all ingredients undergo rigorous testing prior to compounding and we have a year’s supply on hand to continue service in the event of a shortage
  • Home Connect provides in-home implanted pump refills and maintenance, allowing patients to avoid trips to healthcare facilities

1 All patient-specific dispenses within maximum concentrations (based on AIS Healthcare in-house data for 120,000 aseptically processed and terminally sterilized patient-specific prescriptions in 2019)

Advanced Infusion Care:

  • Close collaboration with physicians ensures the consistent delivery of patient-specific, specialized in-home infusion services, without patients needing to travel to clinics
  • No product or supply comes from an outside country, and we currently have a stable supply
  • All plasma used in our immunoglobulin infusions is sourced from the United States

AIS Healthcare Ophthalmics:

  • Our compounding facilities meet all USP <797> standards for sterility and patient safety, and our environmental monitoring exceeds these standards
  • We have a large, local inventory of our most commonly used medications, helping to ensure consistent supply
  • All extended-BUD products undergo sterility testing

Additionally, AIS Healthcare has a preparedness and business continuity plan in place, which has been communicated to all staff members.

Additional COVID-19 response measures:

  • Starting March 10, AIS Healthcare has limited access to our facilities and implemented enhanced illness screening, based on CDC guidance, for all staff and visitors
  • Vendor interactions have been moved off-site and employees are equipped to work from home where needed
  • We are working with our strategic logistics partners to ensure capacity in and out of our pharmacies
  • All nursing staff members are following the CDC’s COVID-19 guidelines for healthcare personnel and are equipped with additional sterilization equipment
  • All AIS Healthcare nurses are wearing personal protective equipment (PPE) while inside patients’ homes, and are educating patients and caregivers on CDC-recommended preventative measures, including hand hygiene

If you have any questions about AIS Healthcare’s response to COVID-19, you can:

AIS Healthcare
18451 Dallas Parkway
Suite 150
Dallas, TX 75287

623 Highland Colony Parkway
Suite 100
Ridgeland, MS 39157

P: 877.443.4006
F: 888.298.2220

About AIS Healthcare
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery (TDD), infusion care and ophthalmology solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.

Learn more at

AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).

Watch our webinar, hosted April 9th, in response to COVID-19: Managing Pumps in the New Paradigm. The webinar provides insights into the pandemic and best practices on adapting your targeted drug delivery care models from members of our medical advisory board and physician partners. 

If you have any questions, please contact us or find your rep to learn more.

Webinar agenda: 

  • Welcome and introduction
    Dr. Anish Patel, Chief Medical Officer of AIS Healthcare
  • COVID-19 update
    Dr. Peter Staats, Chief Medical Officer of National Spine and Pain Centers
  • AIS Healthcare’s response to COVID-19
    Dr. Amitabh Gulati, Director of Chronic Pain at Memorial Sloan Kettering Cancer Center
  • The new paradigm and how AIS Healthcare can help
    Dr. Anjum Bux, Director of Chronic Pain Management at Ephraim McDowell Regional Medical Center
  • Triaging and workflow during COVID-19
    Dr. Michael Danko, Premier Pain Treatment Institute
  • Panel Q&A and close
    Dr. Anish Patel, Chief Medical Officer of AIS Healthcare

April 29, 2020

AIS Healthcare goes above and beyond to supply needed medication for COVID-19
ventilator patients

AIS Healthcare is leveraging its industry-leading 503A compounding facilities to help address a national medication shortage while continuing to provide existing patients with medications of the highest quality and sterility.

Dallas, Texas—As part of our commitment to doing what’s right—not just what’s expected—in response to the coronavirus disease 2019 (COVID-19), AIS Healthcare is working with hospital systems across the country to produce in-demand medications for ventilator patients. AIS Healthcare has provided fentanyl to hospitals in Georgia, Maryland and Washington, D.C.

“We want to help and we are thrilled that we could help the healthcare community,” said Blaine Forshage, Chief Commercial Officer of AIS Healthcare.

A national medication shortage for ventilator patients

Ventilators have become life-saving tools in the fight against COVID-19. However, the use of ventilators requires certain opioid medications, including fentanyl, morphine and hydromorphone, that have long been on the drug shortage list. The growing number of COVID-19 patients on ventilators has exhausted the supply of these medications at many hospitals and traditional suppliers are unable to meet current needs.

Proactively supporting patients and providers during a critical time

AIS Healthcare’s state-of-the-art facilities are fully equipped to compound these specialty
medications for ventilator patients with COVID-19. We’re proactively engaging with regulators and hospitals to be able to leverage our capabilities to produce needed medications and get them to where they’re needed most.

For example, when Chief Executive Officer Simon Castellanos learned that Phoebe Putney Health System in Georgia needed fentanyl for its ventilator patients, he quickly took action. The AIS Healthcare team, spearheaded by Jonathan Hamer, Director of Pharmacy and Pharmacist in Charge for the Dallas pharmacy, worked over the weekend to deliver critically needed drugs to the hospital system.

“We’re committed to doing what’s right, not just what’s expected—and producing these medications is what’s right,” said Castellanos. “We’re able to safely and efficiently produce in-demand medications, and we will keep working with hospital partners to use our capabilities to fight this pandemic.”

In addition to addressing the COVID-19 shortages, AIS Healthcare continues to produce high-quality, patient-specific prescriptions for more than 30,000 targeted drug delivery patients and provide comprehensive care services to help them thrive.

About AIS Healthcare

Advancing quality. Improving lives.
As the leading provider of targeted drug delivery (TDD), infusion care and ophthalmology solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.

Learn more at

Phone 877.443.4006

Simon Castellanos, Chief Executive Officer

Blaine Forshage, Chief Commercial Officer

John Finley, General Counsel and Chief Compliance Officer

Jonathan Hamer, Director of Pharmacy and Pharmacist in Charge, Dallas

On April 28, we hosted our second webinar in response to COVID-19: Managing Pumps in the New Paradigm. This webinar offered up-to-date information on the national COVID-19 response and outlook, and included insights on the impact of COVID-19 on academic medical centers. 

If you have any questions, please contact us or find your rep to learn more.